• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TARS2 变异导致组合氧化磷酸化缺陷-21:病例报告及文献复习。

TARS2 Variants Cause Combination Oxidative Phosphorylation Deficiency-21: A Case Report and Literature Review.

机构信息

Department of Pediatrics, Inner Mongolia Maternal and Child Health Hospital, Hohhot, People's Republic of China.

出版信息

Neuropediatrics. 2024 Jun;55(3):178-182. doi: 10.1055/a-1949-9310. Epub 2022 Sep 23.

DOI:10.1055/a-1949-9310
PMID:36150709
Abstract

OBJECTIVE

The aim of the study is to explore the clinical and genetic characteristics of the combined oxidative phosphorylation defect type 21 (COXPD21) caused by the TARS2 compound heterozygous pathogenic variants, and to improve clinicians' awareness of the disease.

METHODS

The proband was a girl of first birth, with repeated refractory hypokalemia, hearing impairment, developmental delay, intellectual disability, developmental retardation after infection, high limb muscle tension, and increased serum lactate as the clinical phenotype. The clinical performance, diagnosis, treatment process, and gene characteristics of COXPD21 caused by TARS2 of the case were analyzed, reviewed, and compared with the literature from the CNKI, Wanfang Data, and biomedical literature database (PubMed) until November 2021.

RESULTS

The child was diagnosed with COXPD21 after two heterozygous variants in the TARS2 gene were found via whole exome sequencing. One of the variants was c.1679(exon14) A > C (p.Asp560Ala) missense, derived from the mother, and the other was c.1036(exon10)C > T (p.Arg346Cys) missense, derived from the father. The literature was searched and reviewed with the keywords "mitochondrial encephalomyopathy," "TARS2," and "combination oxidative phosphorylation deficiency type 21." A total of four complete domestic and foreign cases were collected from the literature search.

CONCLUSION

COXPD21 onset by a complex heterozygous variant of TARS2 causes refractory hypokalemia, which is rarely reported in China and abroad.

摘要

目的

本研究旨在探讨 TARS2 复合杂合致病性变异引起的联合氧化磷酸化缺陷 21 型(COXPD21)的临床和遗传特征,提高临床医生对该病的认识。

方法

先证者为初产妇女孩,临床表现为反复难治性低钾血症、听力障碍、发育迟缓、智力障碍、感染后发育迟缓、四肢肌肉张力增高、血清乳酸增高等。分析、回顾并比较了该病例 TARS2 所致 COXPD21 的临床表型、诊断、治疗过程及基因特征,并与中国知网(CNKI)、万方数据、生物医学文献数据库(PubMed)截至 2021 年 11 月的文献进行了对比。

结果

经全外显子测序发现 TARS2 基因存在 2 个杂合变异,患儿被诊断为 COXPD21。其中一个变异为 c.1679(exon14)A>G(p.Asp560Ala)错义,来自母亲;另一个变异为 c.1036(exon10)C>T(p.Arg346Cys)错义,来自父亲。检索并以“线粒体脑肌病”“TARS2”和“联合氧化磷酸化缺陷 21 型”为关键词查阅文献,共收集到国内外完全病例 4 例。

结论

TARS2 复合杂合变异引起的 COXPD21 发病罕见,中国和国外报道较少。

相似文献

1
TARS2 Variants Cause Combination Oxidative Phosphorylation Deficiency-21: A Case Report and Literature Review.TARS2 变异导致组合氧化磷酸化缺陷-21:病例报告及文献复习。
Neuropediatrics. 2024 Jun;55(3):178-182. doi: 10.1055/a-1949-9310. Epub 2022 Sep 23.
2
Novel TARS2 variant identified in a Chinese patient with mitochondrial encephalomyopathy and a systematic review.在中国一名线粒体脑肌病患者中鉴定出新型TARS2变异体并进行系统综述。
Am J Med Genet A. 2023 Jan;191(1):70-76. doi: 10.1002/ajmg.a.62988. Epub 2022 Oct 11.
3
Novel compound heterozygous TARS2 variants in a Chinese family with mitochondrial encephalomyopathy: a case report.一个中国家庭中伴有线粒体脑肌病的新型复合杂合 TARS2 变异:病例报告。
BMC Med Genet. 2020 Nov 5;21(1):217. doi: 10.1186/s12881-020-01149-0.
4
TARS2 c.470 C > G is a chinese-specific founder mutation in three unrelated families with mitochondrial encephalomyopathy.TARS2 c.470C > G 是三个不相关的线粒体脑肌病家系中的一个中国特异性的起始突变。
Orphanet J Rare Dis. 2024 Oct 11;19(1):376. doi: 10.1186/s13023-024-03365-w.
5
Expanding the Phenotypic Spectrum: Chronic Kidney Disease in a Patient with Combined Oxidative Phosphorylation Defect 21.拓展表型谱:合并氧化磷酸化缺陷21型患者的慢性肾脏病
Balkan J Med Genet. 2024 Mar 12;26(2):59-64. doi: 10.2478/bjmg-2023-0016. eCollection 2023 Dec.
6
Elucidating the molecular mechanisms associated with TARS2-related mitochondrial disease.阐明与TARS2相关的线粒体疾病相关的分子机制。
Hum Mol Genet. 2022 Feb 21;31(4):523-534. doi: 10.1093/hmg/ddab257.
7
VARS2 and TARS2 mutations in patients with mitochondrial encephalomyopathies.线粒体脑肌病患者中的VARS2和TARS2突变
Hum Mutat. 2014 Aug;35(8):983-9. doi: 10.1002/humu.22590. Epub 2014 Jun 24.
8
[SUCLA2-related encephalomyopathic mitochondrial DNA depletion syndrome: a case report and review of literature].[SUCLA2相关的脑肌病性线粒体DNA耗竭综合征:一例报告及文献复习]
Zhonghua Er Ke Za Zhi. 2014 Nov;52(11):817-21.
9
Clinical, neuroradiological, and molecular characterization of mitochondrial threonyl-tRNA-synthetase (TARS2)-related disorder.线粒体苏氨酰-tRNA 合成酶(TARS2)相关疾病的临床、神经放射学和分子特征。
Genet Med. 2023 Nov;25(11):100938. doi: 10.1016/j.gim.2023.100938. Epub 2023 Jul 13.
10
[A family of hereditary protein S deficiency with the onset of pulmonary embolism and literature review].[以肺栓塞起病的遗传性蛋白S缺乏症一家系并文献复习]
Zhonghua Er Ke Za Zhi. 2022 Feb 2;60(2):134-138. doi: 10.3760/cma.j.cn112140-20210915-00797.

引用本文的文献

1
TARS2 c.470 C > G is a chinese-specific founder mutation in three unrelated families with mitochondrial encephalomyopathy.TARS2 c.470C > G 是三个不相关的线粒体脑肌病家系中的一个中国特异性的起始突变。
Orphanet J Rare Dis. 2024 Oct 11;19(1):376. doi: 10.1186/s13023-024-03365-w.
2
Clinical, neuroradiological, and molecular characterization of mitochondrial threonyl-tRNA-synthetase (TARS2)-related disorder.线粒体苏氨酰-tRNA 合成酶(TARS2)相关疾病的临床、神经放射学和分子特征。
Genet Med. 2023 Nov;25(11):100938. doi: 10.1016/j.gim.2023.100938. Epub 2023 Jul 13.